ArticlePDF Available

Perspective of Personalized Cancer Therapy

  • July 2017
DOI:10.19080/AIBM.2017.04.555638
Authors:
Da Yong Lu at Shanghai University
Da Yong Lu
Ting-Ren Lu at Shanghai University
Ting-Ren Lu
Bin Xu at Shanghai University
Bin Xu
Jian Ding at Harvard Medical School
Jian Ding
Show all 6 authorsHide
Download full-text PDF
Read full-text
Download citation
Content uploaded by Da Yong Lu
Author content
All content in this area was uploaded by Da Yong Lu on Jul 26, 2017
Content may be subject to copyright.
Perspective
Volume 4 Issue 3 - July 2017
DOI: 10.19080/AIBM.2017.04.555638
Adv Biotech & Micro
Copyright © All rights are reserved by Da-Yong Lu
Perspective of Personalized Cancer Therapy
Da-Yong Lu1*, Tig-Ren Lu1, Bin Xu2, Jian Ding2, Yi Lu3 and Nagendra Sastry Yarla4
1Shanghai University, China
2Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China
3Shanghai Ocean University, China
4GITAM University, India
Submission: June 14, 2017; Published: July 24, 2017
*Corresponding author: Da-Yong Lu, Shanghai University, Shanghai200444, PRC, China, Email:
Introduction
PCT is imperfect now and in their initial stages due to
unsatisfactory clinical outcomes and relatively higher costs in
some of the strategies. There are several key factors for these
unsatisfactory results. My early gives a panorama of currently
applied PCT strategies, especially the drawback of every PCT
(individualized cancer chemotherapy, ICC) strategies-drug
sensitivity testing (DST), cancer biomarkers, bioinformatics,
pharmacogenetics (PG), anti metastatic therapy, drug
combination, assistant chemotherapy, cost-effective [1-7]. It
serves as a platform or media for discussion and promotion of
these ICC strategies.
Which strategy is more powerful?
DST and PG are the mainstream of current PCT/ICT) [8,9].
By analyzing different available PCT/ICT strategies, we suggest
the equal importance of every type of ICC strategies by now.
Our argument is based on current clinical practice. DST is
unsatisfactory now. Patients’ survival has improved very little
in spite of utilization of DST [10,11]. Many factors, such as
increasing drug number in the DST, development of more active

this condition [10,11]. The more effective and selective
anticancer or anti metastatic drugs are developed [12-15], the
more favorable outcomes that DST and PG can make because
there are better choices of drug armaments [8,9].
Sequencing cancer genomes has gradually increased our
power to pinpoint to tumor biomarkers. Detection of human or
cancer genetic, transcript, protein or glycoprotein molecular and
bioinformatics need less and less moneys in future. The cancer
biomarker or bioinformatics detection-based ICT strategy will
also update with times and lower cost with technical innovations
and might be the most potential ICC strategies in the future [9].
A recent genomic study of >3,000 tumors across 26 cancer
types has been underway. Only 1/4 of these tumors contain
known cancer genes [8]. It means that most tumors are caused
         
further investigations of cancer biomarkers.
Now PCT/ICT can be mainly divided into DST, PG and
cancer biomarker detection. In future, new disciplines such as
individualized anti metastatic chemotherapy and individualized
assistant chemotherapy may soon come into reality. The greatest
drawbacks of present individualized cancer chemotherapy are
designed to target primary tumors rather than metastatic
Adv Biotech & Micro 4(3): AIBM.MS.ID.555637 (2017) 001
Abstract
Personalized medicine is a new frontier in modern medicine. Personalized cancer therapy (PCT) has been developed over 60 years. But,

Keywords: Personalized cancer therapy; Individualized cancer therapy; Drug sensitivity testing; cancer biomarker; Pharmacogenomics; Anti
metastatic therapy; Drug combination; Assistant chemotherapy
How to cite this article: Da-Yong L, Tig-Ren L, Bin X,et al. Perspective of Personalized Cancer Therapy. Adv Biotech & Micro. 2017; 4(3): 555638. DOI:
10.19080/AIBM.2017.04.555638.
002
Advances in Biotechnology & Microbiology
lesions. Individualized antimetastatic chemotherapy might be
the key of future strategy. We are sure that future trend is to
introduce integrated ones of PCT/ICT [9].
Cooperation of all strategies
A lot of hospitals never try of any ICT strategies. In future,
ICT strategies should be improved and perfected for survival
 
we try different types of ICT strategies in the clinics, the more
satisfactory outcome we may obtain. .
The ultimate goal is to markedly decrease death from
cancer. To guide therapeutics, ICT strategies seem to be one
of best options for cancer treatment. No matter which type of
ICC strategies is used in clinics, it ought to be effective and in
reasonable cost. According to this rule, future types of PCT/ICT
   
[9,16,17].

ICT, but many main obstacles still need to be hurdled. For one
important reason is there is less improvement in cancer patients’
survival in spite of applications of some types of ICC. But it can
be a future miracle if we can perfect them into a successful one.
So are we ready for that yet? [17].
References
1. Lu DY (2014) Drug sensitivity testing. In: Lu DY (Ed.), Personalized
Cancer Chemotherapy, An Effective Way for Enhancing Outcomes in
Clinics. Chapter 2, Woodhead Publishing, Elsevier, UK, pp. 5-12.
2. Lu DY (2014) Individualized cancer chemotherapy via cancer
biomarkers or bioinformatics detecting. In: Lu Da-Yong (Ed.),
Personalized Cancer Chemotherapy, An Effective Way for Enhancing
Outcomes in Clinics. Chapter 3, Woodhead Publishing, Elsevier, UK, pp.
13-20.
3. Lu DY (2012) pharmacogenetics Personalized Cancer Chemotherapy,
An Effective Way for Enhancing Outcomes in Clinics. In: Lu Da-Yong
(Ed.), Chapter 4, Woodhead Publishing, Elsevier, UK, pp. 21-28.
4. Lu DY (2014) Individualized antimetastatic therapy. In: Lu Da-Yong
(Ed.), Personalized Cancer Chemotherapy, An Effective Way for
Enhancing Outcomes in Clinics. Chapter 5, Woodhead Publishing,
Elsevier, UK, pp. 29-36.
5. Lu DY (2014) Drug combinations. In: Lu Da-Yong (Ed.), Personalized
Cancer Chemotherapy, An Effective Way for Enhancing Outcomes in
Clinics. Chapter 6, Woodhead Publishing, Elsevier, UK, pp. 37-42.
6. Lu DY (2014) Assistant chemotherapy. In: Lu Da-Yong (Ed.),
Personalized Cancer Chemotherapy, An Effective Way for Enhancing
Outcomes in Clinics. Chapter 7, Woodhead Publishing, Elsevier, UK, pp.
43-48.
7. Lu DY (2014) Cost-effectiveness consideration. In: Lu Da-Yong (Ed.),
Personalized Cancer Chemotherapy, An Effective Way for Enhancing
Outcomes in Clinics. Chapter 8, Woodhead Publishing, Elsevier, UK, pp.
49-59.
8. Lu DY, Lu TR, Chen XL, Ding J (2012) Individualized cancer
chemotherapy. In: Shoja MM, Agutter PS, Tubbs RS, Ghanei M, Ghabili
K, et al. (Eds.), Hypotheses in Clinical Medicine. Chapter 13, Nova
Publisher, US, pp.199-216.
9. Lu DY, Chen XL, Ding J (2006) Individualized cancer chemotherapy
       
computational coordination-an effective strategy to improve clinical
treatment. Medical Hypotheses 66(1): 45-51.
10. Lu DY, Lu TR, Ding J, Xu B, Che JY, et al. (2015) Anticancer drug
sensitivity testing, a historical review and future perspectives. Current
Drug Therapy 10(1): 44-55.
11. Volm M, Efferth T (2015) Prediction of cancer drug resistance and
implications for personalized medicine. Front Oncol 17(5): 282.
12. Lu DY, Lu TR, Cao S (2012) Cancer metastases and clinical therapies.
Cell Dev Biol 1(4): e110.
13. Lu DY, Lu TR, Wu HY, Cao S (2013) Cancer metastases treatments.
Current Drug Therapy 8(1): 24-29.
14. Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights
and evolving paradigms. Cell 147(2): 275-292.
15. Lu DY, Lu TR, Xu B, Qi RX, Sastry NY, et al. (2016) Cancer metastasis, a
clinical dilemma for therapeutics. Current Drug Therapy 11(2): 163-
169.
16. Lu DY (2014) Personalized cancer chemotherapy, an effective way for
enhancing outcomes in clinics. Woodhead Publishing, Elsevier, UK.
17. Lu DY, Lu TR, Chen XL (2012) Individualized cancer chemotherapy, are
we ready for that yet? Metabolomics 2: e113.
Your next submission with Juniper Publishers
will reach you the below assets
• Quality Editorial service
• Swift Peer Review
• Reprints availability
• E-prints Service
• Manuscript Podcast for convenient understanding
• Global attainment for your research
• Manuscript accessibility in different formats
( Pdf, E-pub, Full Text, Audio)
• Unceasing customer service
Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php
This work is licensed under Creative
Commons Attribution 4.0 Licens
DOI: 10.19080/AIBM.2017.04.555638
... Overall, we welcome all preclinical anticancer drug evaluations, clinical diagnosis and therapeutic selection that can reduce false-positive and false-negative data before the clinical study. This action may greatly reduce the burden of large-scale evaluation and clinical drug selection [89][90][91][92]. ...
... Integrating and comparing information between virtual and reality Ø Drug combination study (either theory, moleculardocking; experimental cytotoxicity and clinical trials) Ø Artificial intelligence in the earliest stage of experimental and clinical diagnosis Ø Personalized medicine in drug selection, such as drug sensitivity testing [89][90][91][92] CONCLUSION Several pathways may be helpful to speed up the discovery and development of anticancer drugs. In the future, higher efficient drug evaluative modalities may continue to promote anticancer drug development and clinical paradigms worldwide. ...
Anticancer Drug Development, Evaluative Architecture
Article
Anticancer drug development is growing complexity and multi-factorials, which demands robust drug evaluative architecture in experimental and preclinical studies. To increase the number of drug licensing, biochemical, pharmacological, technical and economic changes (balance and integration) in evaluative systems should be focused in world labs. Despite a great progress, treatment breakthroughs and drug industry need new minds and more competitive technology (new generation of in vitro test systems) were emerging in the past. Overall, drug evaluative systems consisted half of anticancer drug development and licensing (medicinal chemistry and pharmacology in total) from initial screening to clinical validity. Its advances greatly impact the outcomes of drug production (rates of final drug licensing and efficacy of therapeutics in the clinic). In this regards, creative ideas and new techniques will change the norm and convention of drug screening and mechanic exploration in the future. This article provides multi-disciplinary approaches for experimental and preclinical anticancer drug evaluations, selections and combinations (chemistry and biomedicine). Future trends for drug evaluative systems are especially highlighted in depth, multilateral and multidisciplinary.
View
... In summary, different types of nursery play key roles in clinical trials, especially chronic diseases, such as HIV/AIDS treatments, 14 mental diseases, 15-18 bone disorders, 18-21 metabolic diseases, [22][23][24][25][26][27] cancers 28,29 and so on. Familiarity for a variety of different diseases for nurses may help doctors more ...
Nursery Service, Quality Promotion
Article
Full-text available
  • May 2019
Nursery service is the main part of healthcare efforts worldwide. The promotion of nursery science and quality is an indispensable avenue for patient’s recovery and survivals until now. Nursing science and quality promotion may be from many pathways, like education improvements, wide-spread of medical knowledge dissemination for nurses and willing to take parts of more responsibility. This short communication addresses parts of these medical challenges and highlights their possible trends in the future.
View
... In summary, different types of nursery play key roles in clinical trials, especially chronic diseases, such as HIV/AIDS treatments [14], mental diseases [15][16][17][18], bone disorders [18][19][20][21], metabolic diseases [22][23][24][25][26][27], cancers [28,29] and so on. To promote medical practice, nurses must play very important responsibility in medical treatments. ...
Nursery Service in Modern Days
Article
Full-text available
  • Apr 2019
Nursery service is the main part of healthcare efforts worldwide. Patient’s recovery and survivals need high quality nursery to support and promotions. In this editorial, many pathways, like education improvements, medical knowledge for nurses and willing to take parts of more responsibility from nursery care are addressed.
View
... In summary, different types of nursery play key roles in clinical trials, especially chronic diseases, such as HIV/AIDS treatments [9], mental diseases [10][11][12][13], bone disorders [14][15][16][17], metabolic diseases [18][19][20][21][22][23], cancers [24][25] and so on. ...
Patient's Care and Nursery in Modern Medicine
Article
Full-text available
  • Feb 2019
A great proportion of healthcare efforts is a modern challenge. The promotion of the quality and diversity of medical nursing is as important as doctorial areas for patient’s recovery and survivals until now. Nursing activity may be expected with growing academic notification and respect (economic and career benefits) globally. This editorial addresses parts of these medical challenges and highlights their possible trends in the future.
View
... In summary, different types of nursery play key roles in clinical trials, especially chronic diseases, such as HIV/AIDS treatments, 9 mental diseases, 10-13 bone disorders, 14-17 metabolic diseases, 18-23 cancers 24,25 and so on. ...
Patient's Care and Nursery in Different Diseases
Article
Full-text available
  • Feb 2019
A great proportion of healthcare efforts for a chronic or dying patient in a general hospital are both physical supports (mobile and medical assistance) and cognitive/ emotional communication (activity of nursing and spiritual promotion). The spiritual part of medical/health efforts is a common-place for disabled patients. The promotion of the quality and diversity of medical nursing is as important as doctorial areas for patient’s recovery and survivals until now. However, currently, nursing activity does not receive enough academic notification and respect (economic benefits) globally. This editorial addresses parts of these medical challenges and highlights their possible trends in the future.
View
Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study
Article
Full-text available
There is growing interest in Phase I dose-finding studies studying several doses of more than one agent simultaneously. A number of combination dose-finding designs were recently proposed to guide escalation/de-escalation decisions during the trials. The majority of these proposals are model-based: a parametric combination-toxicity relationship is fitted as data accumulates. Various parameter shapes were considered but the unifying theme for many of these is that typically between 4 and 6 parameters are to be estimated. While more parameters allow for more flexible modelling of the combination-toxicity relationship, this is a challenging estimation problem given the typically small sample size in Phase I trials of between 20 and 60 patients. These concerns gave raise to an ongoing debate whether including more parameters into combination-toxicity model leads to more accurate combination selection. In this work, we extensively study two variants of a 4-parameter logistic model with reduced number of parameters to investigate the effect of modelling assumptions. A framework to calibrate the prior distributions for a given parametric model is proposed to allow for fair comparisons. Via a comprehensive simulation study, we have found that the inclusion of the interaction parameter between two compounds does not provide any benefit in terms of the accuracy of selection, on average, but is found to result in fewer patients allocated to the target combination during the trial.
View
Cancer Metastasis, a Clinical Dilemma for Therapeutics
Article
Full-text available
Background: More than 90% of cancer deaths are caused by cancer metastasis. Cancer metastatic therapy is a top priority topic. Objective: New therapeutics against cancer metastasis is to be discovered. Methods: In the past pathogenesis study, a therapeutic dilemma has been discovered from literatures of epithelial-mesenchymal cell interchange in late-staged cancer patients—opposite tumor pathogenesis routes between primary and metastatic tumors. Results: Possible options for overcoming this dilemma are enlisted from different therapeutic attempts (such as novel drug target (cancer biomarkers) discovery, antimetastatic drug developments, biotherapies, drug combinations, cancer therapeutics according to metastatic cascades, different types of personalized medicine paradigms and so on). Conclusions: These therapeutic options might change the landscape of cancer treatments and managements in clinics forever.
View
Prediction of Cancer Drug Resistance and Implications for Personalized Medicine
Article
Full-text available
  • Jan 2016
Drug resistance still impedes successful cancer chemotherapy. A major goal of early concepts in individualized therapy was to develop in vitro tests to predict tumors’ drug responsiveness. We have developed an in vitro short-term test based on nucleic acid precursor incorporation to determine clinical drug resistance. This test detects inherent and acquired resistance in vitro and transplantable syngeneic and xenografted tumors in vivo. In several clinical trials, clinical resistance was predictable with more than 90% accuracy, while drug sensitivity was detected with less accuracy (~60%). Remarkably, clinical cross-resistance to numerous drugs (multidrug-resistance, broad spectrum resistance) was detectable by a single compound, doxorubicin, due to its multifactorial modes of action. The results of our predictive test were in good agreement with predictive assays of other authors. As no predictive test has been established as yet for clinical diagnostics, the identification of sensitive drugs may not reach sufficiently high reliability for clinical routine. We propose a rethinking of the “chemosensitivity” concept. Instead, predictive in vitro tests may reliably identify drug-resistant tumors. The clinical consequence imply to subject resistant tumors not to chemotherapy, but to other new treatment options such as antibody therapy, adoptive immune therapy, hyperthermia, gene therapy etc. The high accuracy to predict resistant tumors may be exploited to develop new strategies for individualized cancer therapy. This new concept bears the potential of a revival of predictive tests for personalized medicine.
View
Anticancer Drug Sensitivity Testing, a Historical Review and Future Perspectives
Article
Full-text available
Clinical cancer treatment and therapy have been gradually improved by experimental and clinical advancements worldwide, especially after the advent of different types of individualized cancer therapy (ICT) and new generations of anticancer drugs. Despite the long history of anticancer drug sensitivity testing (DST), its therapeutic benefits to clinical cancer patients are compromised and controversial. DST techniques are diversified and improved a great deal, but they have not been developed into an overwhelming means to cure all cancer patients in clinics. The retrospection and panorama of historic and evolutionary developments of DST including clinical relevance, advantageous, technical cautions, limitations or even shortcomings of varied models and methodologies at present stage are addressed. Possible future directions and novel ideas are also discussed and highlighted.
View
Personalized Cancer Chemotherapy: An Effective Way of Enhancing Outcomes in Clinics
Book
Full-text available
  • Dec 2014
Personalized Cancer Chemotherapy separately describes and addresses "individualized cancer chemotherapy" (ICC) strategies new and old, to provide readers with new insights into their characteristics and techniques, as well as key debates and future trends in this area. The book devotes chapters to drug sensitivity testing, cancer biomarkers and bioinformatics detection, pharmacogenetics, individualized antimetastatic therapy, drug combinations, assistant chemotherapy, and cost-effectiveness considerations. A major obstacle to controlling cancer growth and metastases in patients is the inappropriate use of anticancer and antimetastatic drugs. Researchers and clinicians are now beginning to focus on ICC also called "personalized cancer chemotherapy" (PCC), to improve therapeutic quality and outcomes by selecting and prescribing the most appropriate and effective drugs. Using genetic, molecular, and bioinformatics data and modern experimental techniques, known tumor genes can be detected more easily than ever before; the average speed of genetic sequencing has increased 15,000 to 50,000 times since the Human Geonme Project was completed. This book will help readers understand the pros and cons of each individualized cancer chemotherapy strategy from different angles so as to make good judgments and predictions of drug responses and clinical outcomes.
View
Cancer Metastases and Clinical Therapies
Article
Full-text available
  • Jan 2012
More than 90% cancer deaths are caused by cancer metastasis. As cancer metastasis is the main cause of human deaths, we shall pay more attentions on it. Currently, treatment and chemotherapy are focused on primary tumors rather than metastatic processes. Antimetastatic drugs are often used as assistant therapy. So cancer patients' survivals have been improved very little. To change this mindset, we highlight this problem by giving new perspectives and try to improve the outcome of chemotherapy of cancer patients from different possible ways. Human cancer metastasis is a long-evolving, multi-steps process that can only be treated or controlled by drugs or immuno-modulators by now. Human neoplasm metastasis, at least a month-long course, encompasses several different substages and affects or being affected by numerous genes and molecules. We have found that each drug or immuno-modulator might act differently within the various stages of a metastatic course. We, therefore, suggest that future antimetastatic therapy should be strategically optimized according to characteristics of metastatic processes in order to reach maximum therapeutic benefits. In this view, we propose, address and support this issue by using past literature evidence, our experimentations and existing biological, anatomical and pathologic characteristics.
View
Cancer Metastasis Treatments
Article
Full-text available
More than 90% of cancer deaths are caused by cancer metastasis. Since cancer metastasis is the main cause of human deaths, so in this article more attention will be paid to it than ever before. Presently, clinical cancer chemotherapies have been targeting on primary tumors rather than on metastatic processes. Since the antimetastatic drugs are different from antiproliferative drugs and underinvestigated, cancer patients’ survival has been improved on a small scale now. To change this stalemate, this problem is reiterated by an analysis of the relationship between pathology, pharmacology and clinical therapy of neoplasm metastasis and it is suggested to improve the outcome of chemotherapy of cancer patients from different possible ways; e.g. to make more efforts to manufacture new types of antimetastatic drugs and optimize use of these drugs in clinics.
View
Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination - An effective strategy to improve clinical treatment
Article
Full-text available
Most current cancer chemotherapy is unsatisfactory. There is a trend towards changing the norm for drug selection; one approach is to seek individualized cancer chemotherapy (ICC). ICC is an approach to maximizing the efficacy of chemotherapy and reducing its adverse effects to a minimum. It involves choosing anticancer drugs through the following critical steps: (i) performing drug sensitivity tests in vivo and/or in vitro; (ii) analyzing pathogenic information from morphology, histology and bioinformatics, so that targeted therapy can be offered to disrupt the escalating tumorigenic molecules and pathways; (iii) introducing mathematical and computational systems to assist in improving the quality of decision-making. Increasing clinical evidence indicates that drug sensitivity tests, pathological profile analyses and computational coordination are ways to improve therapeutic quality. In future, each patient should have his own unique chemotherapy protocol.
View
Individualized cancer chemotherapy
Article
  • Jan 2013
One of the major obstacles to controlling cancer growth and metastases is theinappropriate use of anticancer drugs. Treatment using individualized cancerchemotherapy (ICC) has been attracting increasing attention and will continue to showbeneficial outcomes in the future. In this chapter, this issue is addressed by discussingspecific strategies for ICC, including drug sensitivity testing, biomarker detection,biomarker-oriented therapy, pharmacogenetics, cancer metastasis-targeted therapy,combined chemotherapy and biotherapy, adjunctive therapy, mathematical techniques,and computational analysis. Many longstanding key debates and future trends are alsodiscussed.
View
Individualized cancer chemotherapy via cancer biomarkers or bioinformatics detection
Chapter
  • Dec 2015
Last 20 years, this world has witnessed the initiation and rapid progression of bioinformatics study. Cancer bioinformatics study is one of such important omics branches for clinical applications. Same as other biological techniques or systems, bioinformatics are not omni-potent. They have their own limits and shortcomings now. This paragraph will offer a panorama of bioinformatics in cancer researches and clinical applications—a mostly developed area of modern cancer therapy and ICC.
View
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Article
  • Oct 2011
Metastases represent the end products of a multistep cell-biological process termed the invasion-metastasis cascade, which involves dissemination of cancer cells to anatomically distant organ sites and their subsequent adaptation to foreign tissue microenvironments. Each of these events is driven by the acquisition of genetic and/or epigenetic alterations within tumor cells and the co-option of nonneoplastic stromal cells, which together endow incipient metastatic cells with traits needed to generate macroscopic metastases. Recent advances provide provocative insights into these cell-biological and molecular changes, which have implications regarding the steps of the invasion-metastasis cascade that appear amenable to therapeutic targeting.
View